Clinical Study
Pancreas Transplantation: Does Age Increase Morbidity?
Table 1
Patient characteristics and donor parameters.
| | <50 years of age
| ≥50 years of age
| P value |
| Male, n (%) | 60 (50%) | 11 (65%) | .27 | Recipient Age | 37 ± 7.0 | 54 ± 3.2 | <.0001 | Body Mass Index (kg/m2) | 25.0 ± 5.0 | 26.1 ± 4.0 | .30 | Age at diagnosis of type 1 DM (years) | 13 ± 6.5 | 21 ± 9.2 | .001 | Duration of type 1 DM prior to transplant (years) | 24 ± 6.8 | 33 ± 9.0 | .0004 | Preoperative Hemodialysis, n (%) | 99 (83%) | 13 (76%) | .50 | HCV, n (%) | 5 (4%) | 0 (0%) | 1.0 |
| Comorbidities: | | | | Hypertension, n (%) | 60 (50%) | 9 (53%) | .85 | Peripheral Vascular Disease, n (%) | 32 (27%) | 9 (53%) | .03 | Coronary Artery Disease, n (%) | 21 (18%) | 8 (47%) | .006 | Cerebrovascular Disease, n (%) | 3 (3%) | 2 (12%) | .12 |
| Preoperative serum albumin (g/dl) | 3.80 ± 0.58 | 3.86 ± 0.64 | .98 |
| CMV Status: | | | | D+/R+, n (%) | 39 (33%) | 4 (24%) | | D−/R+, n (%) | 19 (16%) | 3 (18%) | .90 | D+/R−, n (%) | 31 (26%) | 5 (29%) | | D−/R−, n (%) | 30 (25%) | 5 (29%) | |
| SPK, n (%) | 81 (68%) | 11 (65%) | | PAK, n (%) | 31 (26%) | 6 (35%) | .47 | PTA, n (%) | 7 (6%) | 0 (0%) | |
| Enteric Drainage, n (%) | 100 (84%) | 16 (94%) | .47 | Induction therapy used (yes), n (%) | 65 (55%) | 13 (77%) | .12 |
| Induction Agent: | | | | None, n (%) | 54 (45%) | 4 (23%) | | IL-2RA, n (%) | 51 (43%) | 10 (59%) | .23 | Antithymocyte Globulin, n (%) | 14 (12%) | 3 (18%) | |
| Donor Age (years) | 30 ± 10.4 | 32 ± 10.7 | .52 | Pancreas Cold Ischemia Time (hrs) | 7.8 ± 3.1 | 7.2 ± 3.8 | .52 | HLA Mismatches | 4 ± 1.2 | 4 ± 1.8 | .41 | Duration of follow-up (years) | 5.9 ± 4.5 | 4.8 ± 3.7 | .48 |
|
|
DM = Diabetes mellitus, D = Donor, R = Recipient, IL-2RA = Interleukin-2 Receptor Antagonist, HLA = Human Leukocyte Antigen.
|